Marc Beer and his company have vowed to continue with the development of drugs to treat pelvic floor disorders. This decision comes after the company received a $32 million round of funding from the Series B round accompanied with a $10 million cash in the form of venture debt.
Renovia receives a $42 million donation
Renovia Pharmaceuticals is a Boston-based company that pioneers in the development of therapeutic products for conditions such as urinary incontinence. This medical condition is known to affect about 250 million women across the globe. The company has been at the forefront of developing useful products.
Leva, one of its drugs was recently approved the Food and Drug Administration Agency. Thanks to the Longwood Fund, a group that recently joined the Series B round, Renovia will get to test its latest innovations and commercialize Leva. Perspective Advisors and Missouri-based Ascension Ventures supported the process of raising funds.
Among the professionals delighted to be part of this process is the chief executive officer of Renovia Marc Beer, an experienced professional in the pharmaceutical industry. During a press release to announce this partnership, he talked about how thrilled he was at the prospects of improving the lives of women.
He told members of the press that this funding would assist Renovia to diagnose and ultimately treat women with pelvic floor disorders. He also acknowledged that his company would provide answers to a majority of questions often asked about pelvic disorders. Marc Beer promised that Renovia would contribute to the ongoing research and provide knowledge about this condition.
About Marc Beer
Marc Beer is an innovative professional and the former chief executive officer of Aegerion Pharmaceuticals. He has more than two decades of professional experience in the pharmaceutical, biotechnology, and diagnostic fields. His core specializations are the development and commercialization of medical products. Recently, Marc Beer worked for Aegerion Pharmaceuticals where he assisted the company to go public.
During his tenure at this firm, he has also contributed immensely to the commercialization of JUXTAPID, a drug designed to reduce LDL cholesterol. While working for Aegerion Pharmaceuticals, he also helped establish ViaCell technology, a company involved in the harvesting and storage of umbilical cord stem cells.
Marc Beer has also worked for other biotechnology companies such as Genzyme, a company that pioneers in the manufacture drugs used to treat debilitating diseases. He has also worked for Renovia as the chairman and founding partner.
In 2015, he was invited to be part of the board of directors of Erytech Pharma, a company that publicly traded its stocks. Marc Beer has also contributed to the establishment of the Good Start Genetics, a molecular diagnostics company. This professional is an alma mater of Miami University, Ohio. This businessman currently resides in Massachusetts, United States. Learn more: https://people.equilar.com/bio/marc-beer-aegerion-pharmaceuticals-/salary/78453